News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RDGL
$MNKD MannKind Corporation saw 11.28 million shares of its stock trade hands, that's out of 145.34 million shares outstand. The stock has an average daily volume of 2.19 million shares. After hitting a new 52-week low, MannKind Corporation enters the new trading day with a market cap of 167.14 million, a 50-day SMA of $1.80 and a 200-day SMA of $2.41
ftws
BIOAQ and LIQDQ
Hammer candle nice 1 day consolidation
******)))))) UCPA:)))Discover the fortune that excitingly hidden….))))****
UCPA is very special stock. All my years of digging I never feel so great about a stock that I feel totally secure. UCPA audit financial that is rare in oct land. On top of that! Amazing...absolutely no dilute in the past 6 years. The share structure unchanged since 2012. Massive growth revenue with straight 2 years net profits. IMHO: On track to do 70M this year. In 2017 revenue about 60M with bottom line net profits. The insider holds 75% O/S. Zero long-term debt/liability. Super low float, clean balance sheet, clean trade, move well on every buy or sell.
UCPA CONFIRMED OWN 5% IN LOCAL PLANET. THIS IS SUPER HUGE. LOCAL PLANET MARKET CAP IS 16.75 BILLION WITH ANNUAL REVENUE OF 15 BILLION. NO JOKE!
AMAZING! UCPA INK A NEW CONTRACT WITH NETFLIX, TIME WARNER, AND GLOBAL GAMING, NINJA CASINO. GLOBAL GAMING A PUBLIC TRADE COMPANY 198.6 MILLION REVENUE 1-Q.
Global Gaming appoints Tre Kronor Media as new media agency
http://www.jamma-europe.eu/casino/global-gaming-appoints-tre-kronor-media-as-new-media-agency-11487
https://globalgaming.com/
Here is another article stated more clearly Sweden’s Tre Kronor Founder shareholder of the group. Sweden’s Tre Kronor own 5% Local Planet.
"The group includes ‘founder shareholder’ agencies such as Spain’s Zertem Communication Group, Italy’s Media Italia, Germany’s pilot, France’s CoSpirit MediaTrack, Sweden’s Tre Kronor and India’s Percept Media. It claims it will operate across 40 markets at launch.
http://mandmglobal.com/independent-media-agencies-join-forces-for-global-network-local-planet/
FULL LOCAL PLANET DD $UCPA
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141821078
2010 Revenues: $8.6 million USD
2011 Revenues: $15.5 million USD
2012 Revenues: $18.3 million USD
2013 Revenues: $20.4 million USD
2014 Revenues: $48.1 million USD
2015 Revenues: $39.1 million USD
2016 Revenues: $50.6 million USD
2017 Revenues: $58.8 million USD
HERE ARE SOME OF THEIR CLIENTS. Here's the Link to their site: http://trekronormedia.se
Use Google Chrome to translate the page to English and click on see partners:
********6/21/2018 FULL DD PACKET $UCPA*********
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141714346
I silently following this board and Following you for over 15 years. I normally don't post here at all is because I don't have what you and the board is looking for. Knowing you special on the company with solid fundamentals and earning. I strongly believe UCPA have exactly met your requirements. Please don't underestimate the stock by it trade at one penny. Most people post here are savvy investors, therefore, I will not waste your time to spam the board with nonsense. I urge you to take a good look and a good DD to see if this match your investment style.
I really like UCPA for short and long-term investment. UCPA is very special stock. All my years of digging I never feel so great about a stock that gives me feel totally secure. UCPA audit financial that is rare in oct land. On top of that! Amazing...absolutely no dilute in the past 6 years. The share structure unchanged since 2012. Massive growth revenue with straight 2 years net profits. IMHO: On track to do 70M this year. In 2017 revenue about 60M with bottom line net profits. The insider holds 75% O/S. Zero long-term debt/liability. Super low float, clean balance sheet, clean trade, move well on every buy or sell.
UCPA CONFIRMED OWN 5% IN LOCAL PLANET. THIS IS SUPER HUGE. LOCAL PLANET MARKET CAP IS 16.75 BILLION WITH ANNUAL REVENUE OF 15 BILLION. NO JOKE!
AMAZING! UCPA INK A NEW CONTRACT WITH NETFLIX, TIME WARNER, AND GLOBAL GAMING, NINJA CASINO. GLOBAL GAMING A PUBLIC TRADE COMPANY 198.6 MILLION REVENUE 1-Q.
Global Gaming appoints Tre Kronor Media as new media agency
http://www.jamma-europe.eu/casino/global-gaming-appoints-tre-kronor-media-as-new-media-agency-11487
https://globalgaming.com/
Here is another article stated more clearly Sweden’s Tre Kronor Founder shareholder of the group. Sweden’s Tre Kronor own 5% Local Planet.
"The group includes ‘founder shareholder’ agencies such as Spain’s Zertem Communication Group, Italy’s Media Italia, Germany’s pilot, France’s CoSpirit MediaTrack, Sweden’s Tre Kronor and India’s Percept Media. It claims it will operate across 40 markets at launch.
http://mandmglobal.com/independent-media-agencies-join-forces-for-global-network-local-planet/
FULL LOCAL PLANET DD $UCPA
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141821078
2010 Revenues: $8.6 million USD
2011 Revenues: $15.5 million USD
2012 Revenues: $18.3 million USD
2013 Revenues: $20.4 million USD
2014 Revenues: $48.1 million USD
2015 Revenues: $39.1 million USD
2016 Revenues: $50.6 million USD
2017 Revenues: $58.8 million USD
HERE ARE SOME OF THEIR CLIENTS. Here's the Link to their site: http://trekronormedia.se
Use Google Chrome to translate the page to English and click on see partners:
********6/21/2018 FULL DD PACKET $UCPA*********
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141714346
$ONCI multiple catalysts(financials,PR) send this one up this week check it out!
$PMCB PharmaCyte Biotech CEO and CSO Interviewed About IND, Planned Clinical Trial in Pancreatic Cancer, CRO and More PMCB
Read more: http://www.digitaljournal.com/pr/3794846#ixzz5GzmOBUAq
Go $PMCB
$SAGD chart! >>
About SAGD: South American Gold Corp (SAGD) is an operational management company focused on enhancing shareholder value by acquiring and operating under valued cannabis and tech assets.
Corporate Website: http://www.sagdcorp.co
Media contact: info@sagdcorp.co
General contact: info@sagdcorp.co
$ADGO chart -- looking for 2.50 break today --
$MNKD MannKind and Cipla Enter an Exclusive Marketing and Distribution Agreement for Afrezza® in India MNKD
https://www.nasdaq.com/press-release/mannkind-and-cipla-enter-an-exclusive-marketing-and-distribution-agreement-for-afrezza-in-india-20180509-00868
Thank you sir! Chart...
O can you give me opinion on this chart
$RAD Barchart Opinion 72% "BUY"
https://www.barchart.com/stocks/quotes/rad/opinion
Go $RAD
$DFFN Diffusion Pharmaceuticals Announces Allowances of Two U.S. Patent Applications DFFN
https://finance.yahoo.com/news/diffusion-pharmaceuticals-announces-allowances-two-131500164.html
CHARLOTTESVILLE, Va., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients, today announced receipt of two patent application allowances relating to its lead compound trans sodium crocetinate (“TSC”) in the U.S. The allowances include claims for both method of use and composition of matter.
U.S. patent application number 14/993,047 includes claims relating to treating a number of cancers including brain cancers such as glioblastoma, and cancer of the pancreas, using bipolar trans carotenoids, including TSC, along with chemotherapy and radiation therapy.
U.S. patent application number 14/642,703, includes claims relating to novel compositions of bipolar trans carotenoids, including TSC, for oral delivery.
“We have worked hard to ensure our discoveries are protected and are grateful to receive these patent application allowances. We look forward to these patents being issued in the coming months,” said David Kalergis, Chief Executive Officer of Diffusion Pharmaceuticals. “We believe strong intellectual property protections are vital to Diffusion’s ability to compete in the marketplace and to attract potential strategic partners. As we progress our pivotal Phase 3 study in inoperable glioblastoma patients who are administered TSC along with their standard therapies, we feel that it is imperative that our proprietary position be protected to add increased value to the Company.”
About Diffusion Pharmaceuticals Inc.
Diffusion Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on improving patient outcomes in unmet medical needs using its novel small molecule trans sodium crocetinate (TSC). Diffusion is developing TSC for use in conditions where hypoxia (oxygen deprivation) is known to diminish the effectiveness of standard of care (SOC) treatments. In oncology, TSC targets the cancer's hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more vulnerable to the therapeutic effects of SOC treatments without the apparent occurrence of any serious side effects. In non-oncology indications, therapeutic benefit would be achieved directly through re-oxygenation of the tissue threatened with cell death from hypoxia.
A Phase 3 randomized, controlled registration trial with TSC and SOC chemotherapy and radiation, compared with SOC alone in 236 patients newly diagnosed with inoperable glioblastoma multiforme (GBM), a type of brain cancer, is underway. A Phase 2 clinical program was completed in the second quarter of 2015 and evaluated 59 patients with newly diagnosed GBM. This open-label, historically controlled study demonstrated a favorable safety and efficacy profile for TSC combined with SOC, including a 37% improvement in overall survival compared with the control group at two years. A particularly strong efficacy signal was seen in the subset of inoperable patients where survival of TSC-treated patients at two years was nearly four-fold higher compared with the controls. Due to its novel mechanism of action, TSC has safely re-oxygenated a range of tumor types in preclinical and clinical studies. Diffusion believes the therapeutic potential of TSC is not limited to specific tumors, thereby making it potentially useful to improve SOC treatments of other life-threatening cancers. Additional studies under consideration include Phase 2 trials in pancreatic cancer and brain metastases, with study initiation subject to receipt of additional funding or collaborative partnering. The Company also believes that TSC has potential application in other indications involving hypoxia including stroke, where the Company recently announced its PHAST-TSC study which will be conducted in co-operation with the University of California Los Angeles (UCLA) and the University of Virginia (UVA) to test TSC in stroke patients in an in-ambulance clinical trial setting.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the company's plans, objectives, expectations and intentions with respect to future operations and products, the potential of the company's technology and product candidates, the anticipated timing of future clinical trials and protocol review, and other statements that are not historical in nature, particularly those that utilize terminology such as "would," "will," "plans," "possibility," "potential," "future," "expects," "anticipates," "believes," "intends," "continue," "expects," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause the company's actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular uncertainties and risks include: general business and economic conditions; the company's need for and ability to obtain additional financing; and the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, and the various risk factors (many of which are beyond Diffusion’s control) as described under the heading “Risk Factors” in Diffusion’s filings with the United States Securities and Exchange Commission. All forward-looking statements in this news release speak only as of the date of this news release and are based on management's current beliefs and expectations. Diffusion undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
|
Followers
|
634
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
42897
|
|
Created
|
01/09/13
|
Type
|
Free
|
| Moderator ospreyeye | |||
| Assistants mick jjr04001 TheTradingNinja $Pistol Pete$ | |||
| PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
|
Posts Today
|
0
|
|
Posts (Total)
|
42897
|
|
Posters
|
|
|
Moderator
|
|
|
Assistants
|
